LAC 50:V.120
LAC 50:V.120. Coverage of Gene Therapies for Sickle Cell Disease
Cite as La. Admin. Code tit. 50, pt. V, § 120
A. Effective for dates of service on or after July 1, 2025, gene therapies for sickle cell disease administered during an inpatient stay shall be reimbursed outside of the per diem rate for the inpatient stay. Claims for gene therapies for sickle cell disease shall be reimbursed at actual acquisition cost.